Epnone 25mg Tablet contains Eplerenone, a selective aldosterone receptor antagonist indicated primarily for the management of hypertension and heart failure post-myocardial infarction. Eplerenone functions by competitively blocking aldosterone at mineralocorticoid receptors, thereby reducing sodium retention, potassium excretion, and mitigating myocardial and vascular fibrosis. This pharmacological action contributes to decreased blood pressure and improved cardiac remodeling. Epnone is prescribed to patients with essential hypertension, as well as those with left ventricular dysfunction following a heart attack, to reduce morbidity and mortality associated with cardiovascular events. The recommended dosage is typically 25mg once daily, which may be adjusted based on clinical response and renal function. Caution is advised in patients with impaired renal function or hyperkalemia, as Eplerenone may increase serum potassium levels. Regular monitoring of electrolytes and renal parameters is essential during therapy. Epnone is contraindicated in patients with hyperkalemia, significant renal impairment, or hypersensitivity to Eplerenone. Common adverse effects include hyperkalemia, dizziness, and gastrointestinal disturbances. Epnone 25mg Tablet should be used under medical supervision with appropriate monitoring to ensure efficacy and safety in managing cardiovascular conditions.